The estimated Net Worth of Robert J Del Aversano is at least $508 Thousand dollars as of 9 February 2023. Mr Aversano owns over 40 units of OncoSec Medical Inc stock worth over $282 and over the last 7 years he sold ONCS stock worth over $4,648. In addition, he makes $503,034 as VP of Fin. and Principal Accounting Officer & Controller at OncoSec Medical Inc.
Sign up
Mr CPA ONCS stock SEC Form 4 insiders trading
Mr has made over 8 trades of the OncoSec Medical Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 40 units of ONCS stock worth $55 on 9 February 2023.
The largest trade he's ever made was selling 453 units of OncoSec Medical Inc stock on 1 May 2021 worth over $2,202. On average, Mr trades about 178 units every 46 days since 2018. As of 9 February 2023 he still owns at least 1,008 units of OncoSec Medical Inc stock.
You can see the complete history of Mr Aversano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Robert J. DelAversano CPA biography
Robert J. DelAversano CPA is the VP of Fin. and Principal Accounting Officer & Controller at OncoSec Medical Inc.
What is the salary of Mr CPA?
As the VP of Fin. and Principal Accounting Officer & Controller of OncoSec Medical Inc, the total compensation of Mr CPA at OncoSec Medical Inc is $503,034. There are 1 executives at OncoSec Medical Inc getting paid more, with Daniel O'Connor having the highest compensation of $1,176,720.
How old is Mr CPA?
Mr CPA is 49, he's been the VP of Fin. and Principal Accounting Officer & Controller of OncoSec Medical Inc since . There are 7 older and 3 younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.
What's Mr CPA's mailing address?
Robert's mailing address filed with the SEC is 103 CARNEGIE CENTER, SUITE 300, PRINCETON, NJ, 08540.
Insiders trading at OncoSec Medical Inc
Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha, and Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.
What does OncoSec Medical Inc do?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
What does OncoSec Medical Inc's logo look like?
Complete history of Mr Aversano stock trades at Acasti Pharma Inc, OncoSec Medical Inc, and U.S. Gold Corp
OncoSec Medical Inc executives and stock owners
OncoSec Medical Inc executives and other stock owners filed with the SEC include:
-
Daniel O'Connor,
President, Chief Executive Officer, Director -
Robert J. DelAversano CPA,
VP of Fin. and Principal Accounting Officer & Controller -
Margaret Dalesandro,
Independent Chairman of the Board -
Herbert Lyerly,
Independent Director -
Chao Zhou,
Director -
Yuhang Zhao,
Director -
Kevin Smith,
Director -
Robert DelAversano,
Principal Accounting Officer, Controller -
Robert Ward,
Independent Director -
James DeMesa,
Independent Director -
Joon Kim,
Director -
Dr. Mai Hope Le M.D.,
Consultant -
Dr. Sandra Aung Ph.D.,
Sr. VP & Chief Clinical Devel. Officer -
Tu Diep M.Sc.,
Sr. VP & Head of Operations -
Dr. Kim Jaffe,
Assistant VP of Bus. Devel. & Operations -
Robert Hamilton Pierce,
Chief Medical Officer -
Sheela Mohan Peterson,
Chief Legal Officer -
Sharron E Gargosky,
Chief Clinical & Reg. Officer -
Anthony E Iii Maida,
Director -
Mai Hope Le,
Chief Medical Officer -
Richard B Slansky,
Chief Financial Officer -
Avtar S Dhillon,
Director -
Punit Dhillon,
President and CEO -
Annalisa Jenkins,
Director -
Gregory T. Mayes,,
Director -
Sara Bonstein,
CFO/COO -
Spahr Stephany Foster,
Director -
Veronica Vallejo,
Chief Financial Officer -
Grand Pharmaceutical & Heal...,
-
Kellie Malloy Foerter,
Chief Operating Officer -
Holdings, Inc. Alpha,
Director -
Brian A Leuthner,
Interim CEO -
Robert H. Arch,
President and CEO